Four companies, including Lipu Technology, have changed their status for IPO review on the Shanghai Stock Exchange to "suspended (financial report update)".

The Shanghai Stock Exchange website shows that on December 31st, Leap Technology, Power Construction New Energy, Anshi Bio, and Tennmaibao have a total of 4 companies IPO audit status updated to "suspended (financial report update)". According to the prospectus, Leap Technology focuses on the development of high-end semiconductor specialized equipment through advanced precision laser technology and semiconductor innovative process development, and provides related technical services. During the reporting period, Leap Technology's related equipment has been successfully applied to advanced process 3D NAND Flash storage chips, advanced process DRAM storage chips, 28nm and below advanced process logic chips, SiC power chips, trench gate IGBT power chips, advanced power management chips, BSI-CCD chip production, as well as domestic HBM chip process research and development and other cutting-edge applications. Power Construction New Energy's main business is the development, investment, operation, and management of wind power and CECEP Solar Energy generation projects in China, with electricity as the main product. The company is fully engaged in wind power generation and CECEP Solar Energy generation businesses, with assets located in 28 provinces (autonomous regions, municipalities directly under the central government) throughout the country. By the end of the reporting period, the company's installed capacity of controlled power generation projects was 21,246.61 MW, including 9,890.09 MW for wind power generation projects and 11,355.52 MW for CECEP Solar Energy generation projects. Anshi Bio is an innovative biopharmaceutical company entering the commercialization stage, focusing on disease areas such as tumors with significant unmet clinical needs, committed to providing high-quality innovative anti-tumor drugs through efficient independent research and development to enhance patients' quality of life. Around important tumor driver gene pathways such as MET, EGFR, ROS1, NTRK, HER2, RAS, the company has established a multi-level innovative drug pipeline with industry competitiveness and commercial potential. Tennmaibao is an innovative biopharmaceutical company dedicated to blood product replacement therapy for the global market. The company's core product, Staduta monoclonal antibody injection (TNM002), was approved for listing in China in February 2025, making it the world's first recombinant anti-tetanus toxin monoclonal antibody drug of its kind. It has been recognized by China's CDE as a breakthrough therapeutic drug and included in the priority review program. The company's other core product, Recombinant anti-respiratory syncytial virus monoclonal antibody TNM001, is a potential global third and China's first long-acting anti-RSV monoclonal antibody drug for both healthy and high-risk infants. As of the signing date of this prospectus, TNM001 is undergoing clinical phase III trials.